Milestone Pharmaceuticals Inc.
MISTMilestone Pharmaceuticals Inc. in brief
Milestone Pharmaceuticals Inc. is a listed company in the Biotechnology industry, based in Canada. It was founded in 2003. Its market value was $98 M on 30 October 2026, which makes it the 18,770th largest listed company in the world and the 709th largest in Canada on this site. It employs about 38 people and Joseph Oliveto is its chief executive. Its shares trade under the symbol MIST (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Milestone Pharmaceuticals Inc.
We are currently focusing our efforts and financial resources on (i) the commercialization of CARDAMYSTTM (etripamil) nasal spray for the treatment of PSVT, (ii) the development of etripamil for the treatment of AFib-RVR and (iii) corporate development activities that have the potential to increase company value through strategic collaborations.
On December 12, 2025, we announced that the FDA approved our first commercial product, CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of PSVT, to sinus rhythm in adults. We are focused on the commercialization of CARDAMYST, which became available in retail pharmacies in the first quarter of 2026. We manufacture CARDAMYST with a global supply chain that produces the active pharmaceutical ingredient, etripamil, and then formulates and assembles it into the delivery device, a nasal spray, before completing packaging of the saleable product which is then distributed via a third party logistics provider to wholesalers for delivery to retail pharmacies once prescriptions are received. To create demand, our sales team of approximately 60 representatives expects to engage healthcare providers who we believe will treat around 500,000 patients with a diagnosis of PSVT in 2026.
From the company's annual report filed with the US SEC: read the report
Milestone Pharmaceuticals Inc. timeline
- 2003
- 🏁· approximateFounded
- 2007
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2019
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 9 May 2019; shares registered for exchange trading on 6 May 2019.
Events of Milestone Pharmaceuticals Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Canada: #335 (Jan 2020) · #412 (Jan 2021) · #550 (Jan 2022) · #565 (Dec 2022) · #628 (Jul 2023) · #700 (Jan 2024) · #37 (Mar 2026) · #486 (Aug 2026) · #734 (Oct 2026) · #709 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 2.4×
- Free cash flow yield
- -50.2%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -151.0%
- Liabilities / assets
- 63.2%
- Net debt
- $-16M
- Profit per employee
- $-1.7 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-62M | $-63M | — |
| Dec 2024 | — | — | $-42M | $-42M | — |
| Dec 2023 | — | — | $-61M | $-60M | — |
| Dec 2022 | — | — | $-60M | $-58M | — |
| Dec 2021 | — | — | $-43M | $-43M | — |
| Dec 2020 | — | — | $-51M | $-50M | — |
| Dec 2019 | — | — | $-58M | $-55M | — |
| Dec 2018 | — | — | $-24M | $-23M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-49M | $0M | $-49M | $-0.75 | — |
| Dec 2024 | $-29M | $0M | $-29M | $-0.67 | — |
| Dec 2023 | $-46M | $0M | $-47M | $-1.39 | — |
| Dec 2022 | $-52M | $0M | $-53M | $-1.38 | — |
| Dec 2021 | $-33M | — | — | $-1.02 | — |
| Dec 2020 | $-51M | — | — | $-1.70 | — |
| Dec 2019 | $-51M | $0M | $-52M | $-3.50 | — |
| Dec 2018 | $-21M | $0M | $-21M | $72.63 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $3M, net income $-26M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 28, 20268-KCurrent reportListing notice
- Sep 3, 20268-KCurrent reportOther events
- Aug 12, 20268-KCurrent reportResults of operations
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Jun 15, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 13, 20268-KCurrent reportResults of operations
- May 13, 202610-QQuarterly report · period to Mar 2026
- Apr 30, 2026DEF 14AProxy statement
- Mar 20, 20268-KCurrent reportResults of operations
- Mar 20, 202610-KAnnual report · period to Dec 2025
- Jan 26, 20268-KCurrent reportOther events
- Jan 13, 20268-KCurrent reportOther events
Official filings of Milestone Pharmaceuticals Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-62 M
- Net income
- $-63 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $114 M
- Total liabilities
- $72 M
- Total equity
- $42 M
As of December-2025
Top 74 institutional investors in Milestone Pharmaceuticals Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Propel Bio Management, LLC | 9,449,727 | +2,020,137 (+27.19%) | 7.59% | $8 M | Nov 13, 2026 |
| 2 | Pavaki Capital Management LLC | 9,337,848 | +270,000 (+2.98%) | 7.50% | $8 M | Oct 26, 2026 |
| 3 | RTW Investments, LP | 7,833,336 | 0 (0.00%) | 6.29% | $7 M | Nov 16, 2026 |
| 4 | Point72 Asset Management, L.P. | 5,467,247 | +56,109 (+1.04%) | 4.39% | $5 M | Nov 16, 2026 |
| 5 | Simplify Asset Management Inc. | 3,349,379 | 0 (0.00%) | 2.69% | $3 M | Oct 27, 2026 |
| 6 | Millennium Management LLC | 2,235,274 | -906,945 (-28.86%) | 1.80% | $2 M | Nov 16, 2026 |
| 7 | Two Sigma Investments, LP | 1,721,021 | -318,994 (-15.64%) | 1.38% | $1 M | Nov 16, 2026 |
| 8 | Kalehua Capital Management LLC | 1,651,258 | -887,216 (-34.95%) | 1.33% | $1 M | Nov 13, 2026 |
| 9 | RVW Wealth, LLC | 1,148,260 | New | 0.92% | $1 M | Oct 6, 2026 |
| 10 | Marshall Wace, LLP | 1,117,642 | -680,053 (-37.83%) | 0.90% | $1 M | Nov 13, 2026 |
| 11 | Lion Point Capital, LP | 820,000 | 0 (0.00%) | 0.66% | $1 M | Nov 16, 2026 |
| 12 | Toronto Dominion Bank | 750,000 | 0 (0.00%) | 0.60% | $1 M | Nov 16, 2026 |
| 13 | Ameriprise Financial Inc | 666,666 | 0 (0.00%) | 0.54% | $1 M | Nov 16, 2026 |
| 14 | Boxer Capital Management, LLC | 666,666 | 0 (0.00%) | 0.54% | $1 M | Nov 16, 2026 |
| 15 | Morgan Stanley | 617,847 | -17,364 (-2.73%) | 0.50% | $1 M | Nov 13, 2026 |
| 16 | UBS Group AG | 465,239 | -164 (-0.04%) | 0.37% | $0 M | Nov 10, 2026 |
| 17 | Aptus Capital Advisors, LLC | 405,000 | +65,550 (+19.31%) | 0.33% | $0 M | Nov 13, 2026 |
| 18 | Guardian Wealth Advisors, LLC / NC | 405,000 | +65,550 (+19.31%) | 0.33% | $0 M | Nov 16, 2026 |
| 19 | Luminus Management LLC | 275,000 | New | 0.22% | $0 M | Nov 16, 2026 |
| 20 | LPL Financial LLC | 274,634 | +53,761 (+24.34%) | 0.22% | $0 M | Nov 6, 2026 |
| 21 | Wealthspire Advisors, LLC | 159,500 | +18,871 (+13.42%) | 0.13% | $0 M | Nov 13, 2026 |
| 22 | Valeo Financial Advisors, LLC | 146,699 | +16,000 (+12.24%) | 0.12% | $0 M | Oct 8, 2026 |
| 23 | Virtu Financial LLC | 113,848 | +102,235 (+880.35%) | 0.09% | $0 M | Nov 17, 2026 |
| 24 | BNP Paribas Financial Markets | 110,918 | -62,786 (-36.15%) | 0.09% | $0 M | Nov 12, 2026 |
| 25 | ADAR1 Capital Management, LLC | 100,000 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
Show all 74: investors 26 to 74
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Susquehanna International Group, LLP | 98,864 | -261,031 (-72.53%) | 0.08% | $0 M | Nov 16, 2026 |
| 27 | Cascades Capital Asset Management, LLC | 83,610 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 28 | Pinnacle Wealth Planning Services, Inc. | 79,070 | New | 0.06% | $0 M | Oct 27, 2026 |
| 29 | HRT Financial LP | 66,528 | New | 0.05% | $0 M | Nov 13, 2026 |
| 30 | XTX Topco Ltd | 62,565 | +36,248 (+137.74%) | 0.05% | $0 M | Nov 16, 2026 |
| 31 | Waterloo Capital, L.P. | 46,633 | New | 0.04% | $0 M | Nov 16, 2026 |
| 32 | October Effect Ltd | 40,000 | 0 (0.00%) | 0.03% | $0 M | Oct 20, 2026 |
| 33 | Focus Partners Wealth | 36,000 | 0 (0.00%) | 0.03% | $0 M | Nov 12, 2026 |
| 34 | Citadel Advisors LLC | 34,375 | +1,488 (+4.52%) | 0.03% | $0 M | Nov 16, 2026 |
| 35 | Mariner, LLC | 27,830 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 36 | State Street Corp | 27,238 | +4,674 (+20.71%) | 0.02% | $0 M | Nov 12, 2026 |
| 37 | Federation des caisses Desjardins du Quebec | 26,805 | -2,976 (-9.99%) | 0.02% | $0 M | Nov 16, 2026 |
| 38 | Raymond James Financial Inc | 26,600 | -3,470 (-11.54%) | 0.02% | $0 M | Nov 12, 2026 |
| 39 | Gsa Capital Partners LLP | 25,468 | New | 0.02% | $0 M | Nov 16, 2026 |
| 40 | Welch & Forbes LLC | 25,000 | 0 (0.00%) | 0.02% | $0 M | Nov 4, 2026 |
| 41 | National Bank Of Canada /fi/ | 23,500 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 42 | Exit Wealth Advisors, LLC. | 22,692 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 43 | Stephenson & Company, Inc. | 20,000 | 0 (0.00%) | 0.02% | $0 M | Oct 30, 2026 |
| 44 | Taylor Financial Group, Inc. | 20,000 | 0 (0.00%) | 0.02% | $0 M | Nov 2, 2026 |
| 45 | Strategic Family Wealth Counselors, L.L.C. | 18,875 | +5,000 (+36.04%) | 0.02% | $0 M | Oct 29, 2026 |
| 46 | Evolve Private Wealth, LLC | 18,104 | New | 0.01% | $0 M | Nov 13, 2026 |
| 47 | Jones Financial Companies Lllp | 16,000 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 48 | Pathstone Holdings, LLC | 15,500 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 49 | AE Wealth Management LLC | 15,000 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 50 | Vision Retirement, LLC | 15,000 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 51 | Earned Wealth Advisors, LLC | 14,756 | 0 (0.00%) | 0.01% | $0 M | Nov 6, 2026 |
| 52 | Bronte Capital Management Pty Ltd. | 14,390 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 53 | Beta Wealth Group, Inc. | 14,127 | 0 (0.00%) | 0.01% | $0 M | Nov 10, 2026 |
| 54 | Cetera Investment Advisers | 13,868 | -2,500 (-15.27%) | 0.01% | $0 M | Nov 13, 2026 |
| 55 | Engineers Gate Manager LP | 13,394 | New | 0.01% | $0 M | Nov 16, 2026 |
| 56 | Jane Street Group, LLC | 13,289 | -44,498 (-77.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 57 | Creative Planning | 13,080 | 0 (0.00%) | 0.01% | $0 M | Nov 2, 2026 |
| 58 | Cantor Fitzgerald, L. P. | 13,000 | New | 0.01% | $0 M | Nov 16, 2026 |
| 59 | Cambridge Investment Research Advisors, Inc. | 12,980 | -13,980 (-51.85%) | 0.01% | $0 M | Nov 2, 2026 |
| 60 | Rockefeller Capital Management L.P. | 12,500 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 61 | Secure Asset Management, LLC | 10,000 | 0 (0.00%) | 0.01% | $0 M | Oct 19, 2026 |
| 62 | Integral Investment Advisors, Inc. | 10,000 | 0 (0.00%) | 0.01% | $0 M | Nov 3, 2026 |
| 63 | Royal Bank Of Canada | 6,698 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 64 | Atlantic Edge Private Wealth Management, LLC | 4,400 | New | 0.00% | $0 M | Oct 20, 2026 |
| 65 | Arax Advisory Partners | 3,684 | +631 (+20.67%) | 0.00% | $0 M | Nov 12, 2026 |
| 66 | US Bancorp \de\ | 3,200 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 67 | PNC Financial Services Group, Inc. | 2,800 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 68 | Wells Fargo & Company/mn | 2,049 | New | 0.00% | $0 M | Nov 16, 2026 |
| 69 | Jpmorgan Chase & Co | 1,663 | New | 0.00% | $0 M | Nov 12, 2026 |
| 70 | Rothwell Investment Advisors, LLC | 600 | — | 0.00% | $0 M | Nov 6, 2026 |
| 71 | Simplex Trading, LLC | 404 | -53,767 (-99.25%) | 0.00% | $0 M | Nov 4, 2026 |
| 72 | Rialto Wealth Management, LLC | 300 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 73 | SBI Securities Co., Ltd. | 14 | +8 (+133.33%) | 0.00% | $0 M | Oct 22, 2026 |
| 74 | Caitong International Asset Management Co., Ltd | 1 | -93 (-98.94%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Milestone Pharmaceuticals Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 40,789 | $0 M | — | <0.01% | −45% | May 31, 2026 |
| 🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc. | 22,564 | $0 M | — | <0.01% | +1.0% | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 10,999 | $0 M | — | <0.01% | −19% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Milestone Pharmaceuticals Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Joseph OlivetoPresident and CEO, Director | Sell10b5-1 plan | -36,500 | $2.260 | $82 K | 446,244 | Form 4 |
| filed | Amit HasijaCFO & EVP of Corp. Development | Option exercise | +20,100 | — | — | 112,093 | Form 4 |
| filed | Jeffrey Edward NelsonChief Operating Officer | Option exercise | +20,100 | — | — | 62,093 | Form 4 |
| filed | Joseph OlivetoPresident and CEO, Director | Option exercise | +66,600 | — | — | 517,267 | Form 4 |
| filed | Lorenz MullerChief Commercial Officer | Option exercise | +20,100 | — | — | 216,586 | Form 4 |
| filed | David BharuchaChief Medical Officer | Option exercise | +20,100 | — | — | 125,426 | Form 4 |
| filed | David BharuchaChief Medical Officer | Sell | -12,245 | $1.930 | — | 113,181 | Form 4 |
| filed | Jeffrey Edward NelsonChief Operating Officer | Sell | -12,245 | $1.930 | — | 49,848 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Milestone Pharmaceuticals Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-5.32 reverse split
Trading halts
- 2025-12-12 23:06 UTC, code T3, resumed 12:05 UTC
- 2025-12-12 16:41 UTC, code LUDP, resumed 16:46 UTC
- 2025-03-28 10:55 UTC, code T3, resumed 11:30 UTC
Fails to deliver
- : 72,545 shares at $0.79
- : 10 shares at $0.69
- : 546 shares at $0.64
- : 34,373 shares at $0.70
- : 756 shares at $0.71
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Milestone Pharmaceuticals Inc. scorecard#
Passes 3 of the 13 checks that could be worked out: strongest in financial health (2 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median2.4×Price to book 2.4× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-50.2%Free cash flow is -50.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.75 vs -0.67Diluted EPS -0.75 in fiscal 2025 against -0.67 the year before (report's currency).
- ✗Net income higher than five years earlier-$63 M-$63 M in fiscal 2025 against -$50 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$63 MNet income -$63 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-229.6%-229.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health2 of 4
- ✓Short-term assets cover short-term liabilities8.0×Current ratio 8.01 at the end of fiscal 2025.
- ✗Debt below equity1.4×Debt to equity 1.37 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $16 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Milestone Pharmaceuticals Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Research and development | 18+26.1%— | 14−53.8%— | 31−22.0%— | 40+3.0%— | 39+12.1%— | 34−17.9%— | 42+149%— | 17—— | |
| General and administrative | 17+3.2%— | 17+5.1%— | 16+1.4%— | 16+26.8%— | 12+20.6%— | 10+46.8%— | 7.0+129%— | 3.1—— | |
| Operating income | −62—— | −42—— | −61—— | −60—— | −43—— | −51—— | −58—— | −24—— | |
| Interest and finance income | 2.9−29.9%— | 4.2+5.0%— | 4.0—— | — | — | — | — | — | |
| Interest expense and finance costs | 3.8+7.2%— | 3.6+40.2%— | 2.6—— | — | — | — | — | — | |
| Income before tax | −63—— | −42—— | −60—— | −58—— | −43—— | −50—— | −55—— | −23—— | |
| Income tax | — | — | — | — | — | −0.0—— | −0.1−176%— | 0.1—— | |
| Net income including minority interests | −63—— | −42—— | −60—— | −58—— | −43—— | −50—— | −55—— | −23—— | |
| Net income attributable to shareholders | −63—— | −42—— | −60—— | −58—— | −43—— | −50—— | −55—— | −23—— | |
| Earnings per share, basic | -0.75—— | -0.67—— | -1.39—— | -1.38—— | -1.02—— | -1.70—— | -3.50r3.50−105%— | 72.63—— | |
| Earnings per share, diluted | -0.75—— | -0.67—— | -1.39—— | -1.38—— | -1.02—— | -1.70—— | -3.50r3.50−105%— | 72.63—— | |
| Shares, weighted average (diluted) | — | — | — | — | — | 29+85.9%— | 16+4845%— | 0.3—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 73+189%64.3% | 25+84.0%33.5% | 14+80.2%18.3% | 7.6−93.3%10.3% | 114+57.8%95.2% | 72−39.7%48.2% | 120+39.4%97.1% | 86—97.6% | |
| Short-term investments | 33−25.8%29.0% | 44−15.0%58.8% | 52−8.3%69.4% | 57—76.5% | 0−100%0.0% | 70—46.7% | — | 0.0—0.0% | |
| Inventory | 0.6—0.6% | — | — | — | — | — | — | — | |
| Current assets | 112+51.4%98.6% | 74+1.2%97.9% | 73+1.7%97.1% | 72−39.6%96.4% | 119−20.0%99.2% | 149+21.4%99.1% | 122+39.1%99.2% | 88—100.0% | |
| Property, plant and equipment | 0.5+159%0.4% | 0.2−28.9%0.3% | 0.3+7.8%0.4% | 0.3+19.5%0.3% | 0.2−30.2%0.2% | 0.3−24.0%0.2% | 0.4+1250%0.3% | 0.0—0.0% | |
| Right-of-use (leased) assets | 1.1−18.0%1.0% | 1.4−28.2%1.8% | 1.9−20.9%2.5% | 2.4+241%3.3% | 0.7−27.4%0.6% | 1.0+87.0%0.7% | 0.5+63.2%0.4% | 0.3—0.4% | |
| Total assets | 114+50.4%100% | 75+0.4%100% | 75+1.0%100% | 74−37.9%100% | 120−20.1%100% | 150+21.5%100% | 123+40.1%100% | 88—100% | |
| Accounts payable | 5.6+192%5.0% | 1.9−51.5%2.6% | 4.0+75.9%5.3% | 2.3−48.4%3.0% | 4.4−5.5%3.7% | 4.6+6.1%3.1% | 4.4+68.1%3.5% | 2.6—3.0% | |
| Current liabilities | 14+72.0%12.3% | 8.1+12.5%10.8% | 7.2+17.7%9.6% | 6.1−9.4%8.2% | 6.8+10.0%5.7% | 6.2−26.0%4.1% | 8.3+83.7%6.7% | 4.5—5.1% | |
| Lease liabilities (non-current) | 0.5−38.3%0.5% | 0.9−40.0%1.2% | 1.5−27.0%1.9% | 2.0+321%2.7% | 0.5−31.9%0.4% | 0.7+278%0.5% | 0.2—0.1% | — | |
| Total liabilities | 72+15.1%63.2% | 62+6.7%82.6% | 58+619%77.7% | 8.1+12.2%10.9% | 7.2+5.7%6.0% | 6.9−19.5%4.6% | 8.5+87.8%6.9% | 4.5—5.1% | |
| Retained earnings | −431—−379% | −368—−487% | −326—−433% | −266—−358% | −208r−206—−174% | −163—−109% | −113—−92.0% | −58—−66.2% | |
| Shareholders' equity | 42+218%36.8% | 13−21.6%17.4% | 17−74.7%22.3% | 66−41.1%89.1% | 113−21.3%94.0% | 143+24.5%95.4% | 115+37.5%93.1% | 84r−55—94.9% | |
| Total equity | — | — | — | — | — | — | 115—93.1% | −55—−62.7% | |
| Total liabilities and equity | 114+50.4%100% | 75+0.4%100% | 75+1.0%100% | 74−37.9%100% | 120−20.1%100% | 150+21.5%100% | 123+40.1%100% | 88—100% | |
| Shares outstanding | 106+99.1%— | 53+59.3%— | 33−2.3%— | 34+14.7%— | 30+0.2%— | 30+21.7%— | 25+4006%— | 0.6—— | |
| Cash-flow statement | |||||||||
| Depreciation and amortization | 0.1+8.6%— | 0.1+14.1%— | 0.1+3.4%— | 0.1−4.3%— | 0.1−4.1%— | 0.1+155%— | 0.0+280%— | 0.0—— | |
| Share-based compensation | 7.5+29.2%— | 5.8−39.4%— | 9.5+5.4%— | 9.0+24.3%— | 7.3+47.2%— | 4.9+315%— | 1.2+88.2%— | 0.6—— | |
| Cash from operating activities | −49—— | −29—— | −46—— | −52—— | −33—— | −51—— | −51—— | −21—— | |
| Capital expenditure | −0.3—— | −0.0—— | −0.1—— | −0.3—— | — | — | −0.4—— | −0.0—— | |
| Cash from investing activities | 11+35.8%— | 8.3+74.2%— | 4.8—— | −57−182%— | 70—— | −70—— | −0.4−102%— | 16—— | |
| Shares issued | 38+37.9%— | 27—— | — | 2.6—— | — | 25—— | — | — | |
| Cash from financing activities | 86+166%— | 32−32.8%— | 48+1448%— | 3.1−38.9%— | 5.1−93.1%— | 73−14.3%— | 85+6.6%— | 80—— | |
| Change in cash | 48+313%— | 12+88.7%— | 6.1—— | −107−355%— | 42—— | −48−240%— | 34−54.9%— | 75—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | 3.0—100% | 0.6—100% | 0.2—100% | — | 0—— | 0—— | 0—— | — | — | — | — | — | |
| Cost of revenue | — | 0.3—11.0% | 0.0—5.7% | 0.0—5.9% | — | 0—— | 0—— | 0—— | — | — | — | — | — | |
| Research and development | 16−4.8%— | 3.5−12.2%117% | 3.5−4.4%628% | 3.3−34.7%1366% | 5.5*+40.1%— | 3.9−0.6%— | 3.7+30.3%— | 5.0+36.8%— | 3.9*−27.7%— | 4.0—— | 2.8—— | 3.6—— | 5.5*—— | |
| Selling, general and administrative | — | 24+207%818% | 23+156%4052% | — | — | 7.9—— | 8.9—— | — | — | — | — | — | — | |
| General and administrative | — | — | — | 4.8−6.6%2027% | 5.1*+27.1%— | 3.3−12.8%— | 3.8−25.5%— | 5.2+30.7%— | 4.0*+18.7%— | 3.7—— | 5.0—— | 4.0—— | 3.4*—— | |
| Total costs and expenses | — | 28+137%945% | 26+109%4685% | 24+16.5%10042% | — | 12—— | 13—— | 21—— | — | — | — | — | — | |
| Operating income | −92—— | −25—−845% | −26—−4585% | −24—−9942% | −17*—— | −12—— | −13—— | −21—— | −12*—— | −9.6—— | −9.7—— | −10—— | −14*—— | |
| Interest and finance income | 5.7+92.0%— | 1.4+64.5%48.5% | 1.7+237%311% | 1.7+148%728% | 0.8*−7.9%— | 0.9−19.1%— | 0.5−56.5%— | 0.7−29.9%— | 0.9*−13.6%— | 1.1—— | 1.2—— | 1.0—— | 1.0*—— | |
| Interest expense and finance costs | 12+219%— | 2.2+126%73.6% | 4.7+397%845% | 4.1+342%1737% | 1.0*+7.2%— | 1.0+7.1%— | 1.0+7.2%— | 0.9+7.2%— | 0.9*+7.2%— | 0.9—— | 0.9—— | 0.9—— | 0.9*—— | |
| Net income including minority interests | −98—— | −26*—−871% | −29*—−5119% | −26—−10952% | −17*—— | −12*—— | −13*—— | −21—— | −12*—— | −9.4*—— | −9.4*—— | −10—— | −14*—— | |
| Net income attributable to shareholders | −98—— | −26—−871% | −29—−5119% | −26—−10952% | −17*—— | −12—— | −13—— | −21—— | −12*—— | −9.4—— | −9.4—— | −10—— | −14*—— | |
| Earnings per share, basic | — | -0.18—— | -0.21—— | -0.20—— | — | -0.12—— | -0.20—— | -0.31—— | — | -0.14—— | -0.14—— | -0.21—— | — | |
| Earnings per share, diluted | — | -0.18—— | -0.21—— | -0.20—— | — | -0.12—— | -0.20—— | -0.31—— | — | -0.14—— | -0.14—— | -0.21—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 144—88.8% | 144+209%88.8% | 170+299%93.4% | 71+58.2%36.8% | 73+189%64.3% | 47+265%53.2% | 42+220%89.6% | 45+345%72.9% | 25+84.0%33.5% | 13—15.5% | 13—14.9% | 10—10.6% | 14—18.3% | |
| Short-term investments | 0.9—0.5% | 0.9−97.5%0.5% | 0.9−4.0%0.5% | 113+938%58.3% | 33−25.8%29.0% | 36−43.6%40.9% | 0.9−98.7%1.9% | 11−86.3%17.6% | 44−15.0%58.8% | 64—76.9% | 70—78.4% | 79—82.7% | 52—69.4% | |
| Receivables | 3.9—2.4% | 3.9—2.4% | 2.7—1.5% | 1.6—0.8% | — | — | — | — | — | — | — | — | — | |
| Inventory | 6.7—4.1% | 6.7—4.1% | 4.7—2.6% | 1.8—0.9% | 0.6—0.6% | — | — | — | — | — | — | — | — | |
| Current assets | 162—99.3% | 162+86.5%99.3% | 180+291%99.3% | 192+218%99.2% | 112+51.4%98.6% | 87+7.0%98.8% | 46−47.2%97.4% | 60−35.6%97.7% | 74+1.2%97.9% | 81—97.9% | 87—97.9% | 94—97.9% | 73—97.1% | |
| Property, plant and equipment | 0.4—0.3% | 0.4+206%0.3% | 0.5+195%0.3% | 0.5+184%0.3% | 0.5+159%0.4% | 0.1−32.3%0.2% | 0.2−28.4%0.3% | 0.2−29.3%0.3% | 0.2−28.9%0.3% | 0.2—0.2% | 0.2—0.2% | 0.2—0.3% | 0.3—0.4% | |
| Right-of-use (leased) assets | 0.7—0.4% | 0.7−28.5%0.4% | 0.8−23.9%0.5% | 1.0−20.5%0.5% | 1.1−18.0%1.0% | 0.9−37.7%1.1% | 1.1−34.0%2.3% | 1.2−30.9%2.0% | 1.4−28.2%1.8% | 1.5—1.8% | 1.7—1.9% | 1.8—1.9% | 1.9—2.5% | |
| Total assets | 163—100% | 163+85.4%100% | 182+283%100% | 194+213%100% | 114+50.4%100% | 88+6.1%100% | 47−46.9%100% | 62−35.5%100% | 75+0.4%100% | 83—100% | 89—100% | 96—100% | 75—100% | |
| Accounts payable | 9.2—5.7% | 9.2+190%5.7% | 8.5+189%4.7% | 10+320%5.2% | 5.6+192%5.0% | 3.2+95.2%3.6% | 2.9+291%6.2% | 2.4+38.0%3.9% | 1.9−51.5%2.6% | 1.6—2.0% | 0.7—0.8% | 1.7—1.8% | 4.0—5.3% | |
| Current liabilities | 26—15.8% | 26+145%15.8% | 22+139%12.2% | 21+61.6%10.8% | 14+72.0%12.3% | 11+100%12.0% | 9.3+103%19.6% | 13+214%20.9% | 8.1+12.5%10.8% | 5.3—6.4% | 4.6—5.1% | 4.1—4.3% | 7.2—9.6% | |
| Lease liabilities (non-current) | 0.0—0.0% | 0.0−97.3%0.0% | 0.2−70.0%0.1% | 0.4−51.7%0.2% | 0.5−38.3%0.5% | 0.5−48.2%0.6% | 0.6−44.6%1.4% | 0.8−42.0%1.2% | 0.9−40.0%1.2% | 1.0—1.2% | 1.2—1.3% | 1.3—1.4% | 1.5—1.9% | |
| Total liabilities | 169—104% | 169+151%104% | 163+151%90.0% | 158+132%81.4% | 72+15.1%63.2% | 67+14.6%76.6% | 65+13.8%137% | 68+21.3%110% | 62+6.7%82.6% | 59—71.0% | 57—64.2% | 56—58.4% | 58—77.7% | |
| Retained earnings | −511—−314% | −511—−314% | −485—−267% | −457—−236% | −431—−379% | −413—−471% | −401—−846% | −388—−627% | −368—−487% | −355—−429% | −346—−387% | −336—−350% | −326—−433% | |
| Shareholders' equity | −6.2—−3.8% | −6.2−130%−3.8% | 18—10.0% | 36—18.6% | 42+218%36.8% | 21−14.6%23.4% | −18−155%−37.4% | −6.1−115%−9.9% | 13−21.6%17.4% | 24—29.0% | 32—35.8% | 40—41.6% | 17—22.3% | |
| Total liabilities and equity | 163—100% | 163+85.4%100% | 182+283%100% | 194+213%100% | 114+50.4%100% | 88+6.1%100% | 47−46.9%100% | 62−35.5%100% | 75+0.4%100% | 83—100% | 89—100% | 96—100% | 75—100% | |
| Shares outstanding | 124—— | 124+46.2%— | 124+133%— | 118+120%— | 106+99.1%— | 85+59.7%— | 53+0.4%— | 53+0.4%— | 53+59.3%— | 53—— | 53—— | 53—— | 33—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.2+92.5%— | 0.1*+128%1.9% | 0.1*+104%10.2% | 0.1+107%23.5% | 0.0*+30.8%— | 0.0*0.0%— | 0.0*+7.7%— | 0.0−3.6%— | 0.0*0.0%— | 0.0*—— | 0.0*—— | 0.0—— | 0.0*—— | |
| Share-based compensation | 7.5+39.9%— | 1.4+8.8%45.9% | 1.3+2.3%239% | 1.3−5.1%539% | 3.6*+141%— | 1.3−10.7%— | 1.3−6.0%— | 1.4−10.6%— | 1.5*−21.5%— | 1.4—— | 1.4—— | 1.5—— | 1.9*—— | |
| Cash from operating activities | −77—— | −25*—−852% | −23*—−4063% | −16—−6745% | −13*—— | −9.7*—— | −13*—— | −14—— | −6.8*—— | −7.0*—— | −6.1*—— | −8.9—— | −9.8*—— | |
| Capital expenditure | −0.4—— | −0.0*—−0.1% | −0.0*—−4.7% | −0.0—−18.9% | −0.3*—— | −0.0*—— | −0.0*—— | −0.0—— | −0.0*—— | −0.0*—— | — | — | −0.0*—— | |
| Cash from investing activities | 35+24.3%— | −0.0*—−0.2% | 112*+1026%20034% | −80−338%−33626% | 2.7*−86.0%— | −35*−640%— | 9.9*+4.9%— | 34—— | 19*+41.4%— | 6.5*—— | 9.5*—— | −27—— | 14*—— | |
| Shares issued | 25—— | 0*—0.0% | 0*—0.0% | 11—4576% | 14*—— | — | — | — | 0*—— | 0*—— | −0.3*—— | 28—— | — | |
| Cash from financing activities | 140+185%— | −0.0*−100%−0.3% | 9.1*+25269%1634% | 94+67296%39645% | 36*+151704%— | 49*+66005%— | 0.0*—— | 0.1−99.6%— | 0.0*+2300%— | 0.1*—— | −0.3*—— | 32—— | 0.0*—— | |
| Change in cash | 98+189%— | −25*−703%−852% | 98*—17605% | −1.7−109%−726% | 26*+111%— | 4.2*—— | −2.6*−183%— | 20—— | 13*+222%— | −0.5*—— | 3.1*—— | −3.6—— | 3.9*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Milestone Pharmaceuticals Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Joseph Oliveto | $2.1 M | $2.9 M | $1.0 M | $86 |
| 2024Joseph Oliveto | $854 K | $945 K | $591 K | $141 |
| 2023Joseph Oliveto | $2.0 M | $454 K | $1.1 M | $42 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Milestone Pharmaceuticals Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 4 · Material agreement 4 · Shareholder vote 3 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 28, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Milestone Pharmaceuticals Inc. compares in Biotechnology
- Market cap$98 M · higher than 36% of 726
- Price / book2.4× · lower than 55% of 534
- FCF yield-50.2% · higher than 24% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Milestone Pharmaceuticals Inc.🇨🇦 | $98 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Milestone Pharmaceuticals Inc.? Verify and update this profile — free
Show Milestone Pharmaceuticals Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.